Form 4: Cero Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Charles Ross Carter, CFO of Cero Therapeutics Holdings, Inc., acquired stock options on March 25, 2024.
Summary
- Charles Ross Carter, the Chief Financial Officer of Cero Therapeutics Holdings, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of stock options on March 25, 2024.
- Carter acquired options to purchase 395,387 shares of common stock at an exercise price of $1.77 per share.
- The options vest in 48 monthly installments, contingent upon continued service.
- The expiration date for the options is March 24, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a company executive.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders, potentially incentivizing him to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of stock option acquisition |
| 03/24/2034 | Expiration date of the stock options |
| 03/27/2024 | Date of Form 4 filing |
Keywords
Form 4, Stock Options, Cero Therapeutics, Insider Trading, Beneficial Ownership, Charles Ross Carter, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.